Cyagen

What if fully human VHH antibodies could be discovered directly in vivo, without camelid immunization or a separate humanization step? Join our upcoming webinar, hosted by Pharma D-mand, to explore HUGO-Nano™, Cyagen’s engineered mouse platform for fully human VHH antibody discovery. Jing (Jenny) Shan, MD, PhD, Chief Scientific Officer at Cyagen, will share how the platform works and walk through discovery and characterization data from DLL3, ANG2, CD8, and TfR1 programs. We’ll explore: 🔹 How fully human VHH antibodies are generated and affinity-matured directly in vivo 🔹 What the data reveal about affinity, specificity, cross-reactivity, and developability 🔹 How VHH formats can be applied to BBB delivery and next-generation multispecific biologics 📅 November 19, 2026 🕙 10:00 AM ET | 4:00 PM CET 💻 Online | Free webinar If you’re evaluating VHH formats for your next antibody discovery program, join us to see the data behind the platform. Register and save your seat. #DrugDiscovery #AntibodyDiscovery #AntibodyEngineering #VHH #SingleDomainAntibodies #BloodBrainBarrier #BispecificAntibodies

Which model fits your pain target, and which endpoints will help you evaluate treatment response? These are key decisions when planning a preclinical pain study. Our upcoming webinar will explore how to connect human target biology, disease-relevant models, and in vivo pharmacology. Join Ivan G-N, Ph.D., Senior Business Development Scientist at Cyagen, to explore: 🔹 Where target-humanized models, including NaV1.7 and NaV1.8, fit into pain research 🔹 How an hSCN10A SD rat case study connects molecular characterization with pharmacological evaluation 🔹 What mechanical, thermal, cold, and functional assessments can reveal in neuropathic pain studies 📅 October 28, 2026 🕗 8:00 AM PDT | 11:00 AM EDT 📍 Live on Zoom Planning a pain study or evaluating model options? Register through the event page and bring your research questions. #PainResearch #DrugDiscovery #PreclinicalResearch #Neuroscience #Cyagen

Research assets, integrated platforms, and translational science.

Research updates across models, targets, and drug development.

New models, emerging targets, and research insights.

Disease models, emerging targets, and translational research.